Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 41 to 50 of 330

TitleReference numberPublishedLast updated
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentTA1036
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Ovarian cancerQS18
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)TA1032
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)TA1024
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatmentsTA1008

Results per page

  1. 10
  2. 25
  3. 50
  4. All